New combo trial hopes to tame advanced breast cancer

NCT ID NCT07427394

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two experimental drugs, camizestrant and atirmociclib, in 24 people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has worsened after prior treatment. The main goal is to check safety and how the body processes the drugs, with early signs of tumor control also measured. This is not a cure; it aims to manage the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

St Louis, Missouri, 63108, United States
Research Site
NOT_YET_RECRUITING

East Providence, Rhode Island, 02915, United States
Research Site
RECRUITING

Nashville, Tennessee, 37203, United States
Research Site
NOT_YET_RECRUITING

Cambridge, CB2 0QQ, United Kingdom
Research Site
RECRUITING

London, EC1M6BQ, United Kingdom
Research Site
NOT_YET_RECRUITING

Manchester, M20 4GJ, United Kingdom